Skip to main content

Table 2 Subgroup analysis of the correlation between LAG3 expression and survival outcomes in patients with solid tumors

From: Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis

Categories

OS

DFS

PFS

RFS

Random effects model

Heterogeneity

P

Random effects model

Heterogeneity

P

Random effects model

Heterogeneity

P

Random effects model

Heterogeneity

P

HR

95% CI

I2

P

HR

95% CI

I2

P

HR

95% CI

I2

P

HR

95% CI

I2

P

Total

1.1

1.01–1.19

70.5%

 < 0.001

0.023

1.41

0.96–2.07

77.5%

 < 0.001

0.078

1.12

0.90–1.39

64.7%

0.001

0.317

0.98

0.81–1.19

70.3%

 < 0.001

0.871

cancer type

                    

 BLCA

1.56

0.85–2.86

69.0%

0.072

0.148

     

1.58

1.12–2.23

0.0%

0.339

0.01

1.97

0.80–4.83

-

-

0.139

 BRCA

0.96

0.89–1.04

59.8%

0.011

0.328

1.32

0.43–4.08

89.1%

 < 0.001

0.632

     

0.87

0.78–0.97

54.3%

0.012

0.01

 CESC

1.76

1.03–3.00

0.0%

0.853

0.038

     

1.16

0.69–1.97

0.0%

0.907

0.569

     

 COAD

     

0.31

0.15–0.64

0.0%

0.707

0.001

          

 COADREAD

0.04

0.00–22.19

–

–

0.322

               

 ESCA

1.07

0.68–1.69

70.4%

0.005

0.767

2.86

1.03–7.94

–

–

0.044

1.47

0.30–7.13

87.2%

0.005

0.632

1.72

1.06–2.79

–

–

0.028

 HNSC

1.16

0.87–1.54

41.8%

0.143

0.316

1.73

0.83–3.61

57.0%

0.127

0.141

0.82

0.57–1.18

0.0%

0.355

0.276

     

 KIRC

3.32

0.82–13.55

0.0%

0.806

0.094

8.92

2.40–33.18

15.7%

0.276

0.001

          

 LIHC

1.76

1.08–2.87

0.0%

0.608

0.024

1.62

1.08–2.41

0.0%

0.856

0.019

          

 NSCLC

1.52

0.30–7.60

-

-

0.612

          

1.55

0.99–2.42

–

–

0.056

 OV

1.25

0.73–2.14

79.3%

0.008

0.419

     

1.39

0.87–2.23

35.2%

0.214

0.168

0.5

0.29–0.85

–

–

0.01

 PAAD

     

1.94

1.20–3.14

–

–

0.007

          

 READ

     

0.73

0.42–1.28

0.0%

0.987

0.269

          

 SARC

          

1.1

1.02–1.19

–

–

0.016

     

 SKCM

1.92

1.15–3.22

0.0%

0.898

0.013

     

1.87

0.88–3.99

–

–

0.106

     

 STAD

1.12

0.31–4.12

92.3%

 < 0.001

0.861

2.65

1.53–4.58

–

–

 < 0.001

0.27

0.11–0.68

–

–

0.005

     

 THCA

1.32

0.67–2.60

  

0.422

          

1.01

0.14–7.31

–

–

0.992

 UCEC

               

2.11

0.41–10.77

69.3%

0.071

0.369

Expression location

 TCs

1.02

0.91–1.14

52.6%

0.025

0.772

1.43

0.86–2.37

47.5%

0.126

0.171

1.1

1.02–1.19

0.0%

0.972

0.014

1.52

0.40–5.82

84.5%

0.002

0.539

 TILs

1.16

1.02–1.31

74.2%

 < 0.001

0.021

1.4

0.85–2.32

81.9%

 < 0.001

0.184

1.08

0.76–1.54

74.4%

 < 0.001

0.664

0.97

0.82–1.15

65.4%

0.008

0.72

 TAMs

1.99

0.93–4.25

–

–

0.076

     

1.87

0.88–3.99

–

–

0.106

     
  1. LAG3, lymphocyte- activation gene 3; CI, confidence interval; DFS, disease-free survival; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; COADREAD, colon adenocarcinoma or/and rectum adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; NSCLC, non-small cell lung carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; TCs, tumor cells; TILs, tumor-infiltrating lymphocytes; TAMs, tumor-associated macrophages
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us